Content area
Full Text
It was champagne toasts and congratulations for Genetronics, Inc. last Tuesday when the local firm entered into comprehensive agreements with Ethicon, Inc., a Johnson & Johnson company.
The alliance involves Genetronics' proprietary drug delivery system for electroporation therapy treatment of cancer. The agreement includes licensing, supply and equity, with Johnson & Johnson making a $6 million investment in Genetronics.
"We now have a strong marketing partner," said Lois Crandell, president and CEO of Genetronics. Crandell said the agreement...